Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Invivyd, Inc. (IVVD : NSDQ)
 
 • Company Description   
INVIVYD INC. is a biopharmaceutical company. It involved in developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. INVIVYD INC., formerly known as Adagio Therapeutics, is based in WALTHAM, Mass.

Number of Employees: 122

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.10 Daily Weekly Monthly
20 Day Moving Average: 2,830,696 shares
Shares Outstanding: 294.61 (millions)
Market Capitalization: $324.07 (millions)
Beta: 0.71
52 Week High: $3.07
52 Week Low: $0.48
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -27.15% -30.71%
12 Week -35.29% -40.18%
Year To Date -55.47% -58.68%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
209 CHURCH STREET
-
NEW HAVEN,CT 06510
USA		 ph: 781-819-0080
fax: -		 investors@invivyd.com https://invivyd.com
 
 • General Corporate Information   
Officers
William Duke, Jr. - Principal Executive Officer; Principal Financial O
Marc Elia - Chairman of the Board of Directors
Tamsin Berry - Director
Ajay Royan - Director
Terrance McGuire - Director

Peer Information
Invivyd, Inc. (CORR.)
Invivyd, Inc. (RSPI)
Invivyd, Inc. (CGXP)
Invivyd, Inc. (BGEN)
Invivyd, Inc. (GTBP)
Invivyd, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00534A102
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/13/26
Share - Related Items
Shares Outstanding: 294.61
Most Recent Split Date: (:1)
Beta: 0.71
Market Capitalization: $324.07 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.15 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.50 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.60
Price/Cash Flow: -
Price / Sales: 5.80
EPS Growth
vs. Year Ago Period: 7.14%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: 21.59%
vs. Previous Quarter: -20.13%
ROE
03/31/26 - -53.48
12/31/25 - -48.65
09/30/25 - -92.97
ROA
03/31/26 - -41.56
12/31/25 - -34.48
09/30/25 - -51.88
Current Ratio
03/31/26 - 6.47
12/31/25 - 7.24
09/30/25 - 2.47
Quick Ratio
03/31/26 - 6.47
12/31/25 - 7.24
09/30/25 - 2.47
Operating Margin
03/31/26 - -138.90
12/31/25 - -98.25
09/30/25 - -119.63
Net Margin
03/31/26 - -138.90
12/31/25 - -98.25
09/30/25 - -119.63
Pre-Tax Margin
03/31/26 - -138.90
12/31/25 - -98.25
09/30/25 - -119.63
Book Value
03/31/26 - 0.69
12/31/25 - 1.04
09/30/25 - 0.40
Inventory Turnover
03/31/26 - -
12/31/25 - -
09/30/25 - -
Debt-to-Equity
03/31/26 - 0.00
12/31/25 - 0.00
09/30/25 - 0.00
Debt-to-Capital
03/31/26 - 0.00
12/31/25 - 0.00
09/30/25 - 0.00
 

Powered by Zacks Investment Research ©